ROLE OF HUMAN PAPILLOMAVIRUS IN CERVICAL NEOPLASIA

本病例对照研究的目的是调查其作用。 人乳头瘤病毒(HPV)DNA 6、11、16、18和31型发挥作用 宫颈上皮内瘤变(CIN)的发生发展 二级和三级，控制已知和可疑的风险因素； HPV DNA类型16、18和31已被发现与 在CIN II和CIN III中，而HPV DNA类型6和11被发现更多 经常出现在CIN I中。这项研究项目假设 患有CIN II和III的女性更有可能患有HPV DNA类型 16岁、18岁和31岁的女性与接受正常宫颈涂片的女性进行比较。 由于HPV通常需要一种相关的致癌剂来 PASS在动物肿瘤恶性转化模型中的作用 生殖器疱疹感染、吸烟和激素避孕药 将被评估为可能的共同致癌物质。 北卡罗来纳州纪念医院(NCMH)肿瘤诊所 将作为CIN II和III AS 100个事件的来源 由NCMH细胞学实验室分类。活组织检查确认 CIN II或CIN III也将是病例状态的要求。200个 NCMH家庭医学门诊患者接受常规PAP 被NCMH细胞学实验室归类为正常的涂片， 将作为控制。另一项宫颈刮片将是 从每个病例和对照中提取HPV DNA进行分型。所有案例 和控制将通过电话采访，以收集 有关潜在混杂因素的信息包括：年龄、种族、 教育，第一次性交的年龄，性伴侣的数量， 烟草使用，性传播病史，以及 所使用的避孕方法。 分层分析和无条件Logistic回归 用来研究HPV DNA类型与 宫颈肿瘤状态，同时控制危险因素。这个 人乳头瘤病毒DNA分型与人类免疫缺陷病毒 假设的共同致癌因素(既往生殖器疱疹 感染、吸烟状况和使用的激素避孕药)会 使用无条件Logistic回归进行评估。

The purpose of this case control study is to investigate the role Human Papillomavirus (HPV) DNA types 6, 11, 16, 18, and 31 play in the development of cervical intraepithelial neoplasia (CIN) levels II and III, controlling for known and suspected risk factors, HPV DNA types 16, 18, and 31 have been found to be associated with CIN II and III, while HPV DNA types 6 and 11 are found more frequently in CIN I. This research project hypothesizes that women with CIN II and III are more likely to have HPV DNA types 16, 18, and 31 compared to women with normal cervical smears. Since HPV usually requires an associated carcinogenic agent for malignant transformation in animal tumor models, the role of past genital herpes infection, smoking, and hormonal contraceptives will be evaluated as possible co-carcinogens. The North Carolina Memorial Hospital (NCMH) Neoplasia Clinic will serve as the source of 100 incident cases of CIN II and III as classified by the NCMH cytology laboratory. Biopsy confirmation of CIN II or III will also be a requirement for case status. 200 NCMH Family Medicine Clinic patients receiving routine Pap smears, classified as normal by the NCMH cytology laboratory, will serve as the controls. An additional cervical scraping will be taken from each case and control for HPV DNA typing. All cases and controls will be interviewed by telephone to collect information on potential confounders including: age, race, education, age at first intercourse, number of sexual partners, tobacco use, history of sexually transmitted diseases, and contraceptive methods used. Stratified analysis and unconditional logistic regression will be used to investigate the relationship between HPV DNA types and cervical neoplasia status, while controlling for risk factors. The possibility of interactions between HPV DNA types and the hypothesized co-carcinogenic agents (past genital herpes infection, smoking status, and hormonal contraceptives used) will be evaluated using unconditional logistic regression.